Combination of immunotherapy with anaerobic bacteria for immunogene therapy of solid tumours

Gene Therapy and Molecular Biology

Volumn 13, Issue 1, 2009, Pages 36-52

  Xu, Jian ^a   Liu, Xiao Song ^b   Zhou, Shu Feng ^c   Wei, Ming Q ^a  

^a GRIFFITH UNIVERSITY   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c RMIT UNIVERSITY   (Australia)

Author keywords

Anaerobic bacteria; Clostridial spores; Hypoxia; Immunotherapy; Tumour microenvironment

Indexed keywords

BACTERIA (MICROORGANISMS); EQUIDAE;

EID: 77649322065     PISSN: 15299120     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (100)

1. Agrawal N, Bettegowda C, Cheong I, et al (2004). Bacteriolytic therapy can generate a potent immune response against experimental tumors. Proc Natl Acad Sci U S A 101, 15172-7.
2. Akasaki Y, Liu G, Matundan HH, et al (2006). A peroxisome proliferator-activated receptor-gamma agonist, troglitazone, facilitates caspase-8 and -9 activities by increasing the enzymatic activity of protein-tyrosine phosphatase-1B on human glioma cells. J Biol Chem 281, 6165-74.
3. Aznavoorian S, Stracke ML, Krutzsch H, Schiffmann E, Liotta LA (1990). Signal transduction for chemotaxis and haptotaxis by matrix molecules in tumor cells. J Cell Biol; 110, 1427-38.
4. Akbulut L, Zhang Y, Deisseroth A (2003). Cytotoxic effect of replication-competent adenoviral vectors carrying L-plastin promoter regulated E1A and cytosine deaminase genes in cancers of the breast, ovary and colon, Cancer Gene Ther 10, 388-95.
5. Bubenik J, Vonka V (2003). MHC class I status of tumours and design of immunotherapeutic strategies. Immunol Lett 90, 177-8.
6. Biswas S, Guix M, Rinehart C, et al (2007). Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression. J Clin Invest 117, 1305-13.
7. Bos R vDP, van der Groep P, Shvarts A, Greijer AE, van der Wall E (2004). Expression of hypoxia-inducible factor-1alpha and cell cycle proteins in invasive breast cancer are estrogen receptor related. Breast Cancer Res 6: R450-9.
8. Burdelya L, Kujawski M, Niu G, et al (2005). Stat3 activity in melanoma cells affects migration of immune effector cells and nitric oxide-mediated antitumor effects. J Immunol 174, 3925-31.
9. Berzofsky JA, Terabe M (2008). NKT cells in tumor immunity: opposing subsets define a new immunoregulatory axis. J Immunol 180, 3627-35.
10. Battaglia M, Gregori S, Bacchetta R, Roncarolo MG (2006). Tr1 cells: from discovery to their clinical application. Semin Immunol 18, 120-7.
11. Bonizzi RP (2007). Welfare and immune response. Veterinary Research Communications 31, 97-102.
12. Cho W. Contribution of oncoproteomics to cancer biomarker discovery (2007). Mol Cancer 6, 25-9.
13. Croker AK, Allan AL (2008). Cancer stem cells: implications for the progression and treatment of metastatic disease. J Cell Mol Med 12, 374-90.
14. Chen ZS, Robey RW, Belinsky MG, et al (2003). Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. Cancer Res 63, 4048-54.
15. Cools N, Ponsaerts P, Van Tendeloo VF, Berneman ZN (2007). Balancing between immunity and tolerance: an interplay between dendritic cells, regulatory T cells, and effector T cells. J Leukoc Biol 82, 1365-74.
16. Caux CD, Schmitt D, Banchereau J (1992). GM-CSF and TNF-alpha cooperate in the generation of dendritic Langerhans cells. Nature 360, 258-61.
17. Clynes RA, Towers TL, Presta LG, et al (2000). Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 6, 443-6
18. Carey RW, Holland JF, Whang HY, Neter E (1967), Bryant B: Clostridial oncolysis in man. Euro J Can 3, 37-46.
19. Christian A Petrulio SK-S, Howard L Kaufman (2006). The tumour microenvironment and implications for cancer immunotherapy. Expert Opinion on Biological Therapy 6, 671-84.
20. Dong H, Chen L (2003). B7-H1 pathway and its role in the evasion of tumor immunity. J Mol Med 81, 281-7.
21. Della Porta M, Danova M, Rigolin GM, et al (2005). Dendritic cells and vascular endothelial growth factor in colorectal cancer: correlations with clinicobiological findings. oncology 68, 276-84.
22. Dean M, Fojo T, Bates S (2005). Tumour stem cells and drug resistance. Nat Rev Cancer 5, 275-84
23. Dranoff G, Jaffee E, Lazenby A, et al (1993). Vaccination with irradiated tumor cells engineered to secrete murine granulocytemacrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A 90, 3539-43.
24. Dang LH, Bettegowda C, Huso DL, Kinzler KW, Vogelstein B (2001). Combination bacteriolytic therapy for the treatment of experimental tumors. Proc Natl Acad Sci U S A 98, 15155-60.
25. Dang LH, Bettegowda C, Agrawal N, et al. (2004). Targeting vascular and avascular compartments of tumors with C. novyi-NT and anti-microtubule agents. Cancer Biol. Ther. 3, 326-337
26. de Jonge-Peeters SD, Kuipers F, de Vries EG, Vellenga E (2007). ABC transporter expression in hematopoietic stem cells and the role in AML drug resistance. Crit Rev Oncol Hematol 62, 214-26.
27. Elke Jäger DJ, Alexander Knuth (2002). Clinical cancer vaccine trials. Current Opinion in immunology 14, 178-82.
28. Frey AB (2006). Myeloid suppressor cells regulate the adaptive immune response to cancer. J Clin Invest 116, 2587-90.
29. Fearon ER, Pardoll DM, Itaya T, et al (1990). Interleukin-2 production by tumour cells bypasses T helper function in the generation of an antitumor response. Cell 60, 397-403.
30. Gro F MS (2006). Design of bifunctional siRNAs: Combining immunostimulation and gene-silencing in one single siRNA molecule. Biochemical and Biophysical Research Communications 352, 642-9.
31. Ganss R (2006). Tumor stroma fosters neovascularization by recruitment of progenitor cells into the tumor bed. J Cell Mol Med 10, 857-65.
32. Glick RP LT, Lin H, Tarlock K, Cohen EP (2006). Immunogene therapy as a treatment for malignant brain tumors in young mice. J Neurosurg 105, 65-70.
33. Gelman AE (2003). Autoimmunity heats up. Nat Med 9, 1465-6.
34. Hallmann R, Horn N, Selg M, Wendler O, Pausch F, Sorokin LM (2005). Expression and function of laminins in the embryonic and mature vasculature. Physiol Rev 85,979-1000.
35. Huang AY, Golumbek P, Ahmadzadeh M, et al (1994). Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264, 961-5.
36. Iwadate Y, Namba H, Tagawa M, et al (1997). Induction of acquired immunity in rats that have eliminated intracranial gliosarcoma cell by the expression of herpes simplex virus thymidine kinase gene and ganciclovir administration. Oncology 54, 329-34
37. Jennifer A L, Philipp K (2006). Recent developments in antibacterial drug discovery: microbe-derived natural products - from collection to the clinic. Expert Opinion on Investigational Drugs 15, 211-26.
38. Koido S, Nikrui N, Ohana M, et al (2005). Assessment of fusion cells from patient-derived ovarian carcinoma cells and dendritic cells as a vaccine for clinical use. Gynecol Oncol 99, 462-71.
39. Kay A (2001). Allergy and allergic diseases. First of two parts. N Engl J Med 344, 30-7.
40. Keith LK BA, David A M, Kathy S, Mary LD (2002). Adoptive T-cell therapy for the treatment of solid tumours. Expert Opinion on Biological Therapy 2, 55-66.
41. Klencke B, Matijevic M, Urban RG, et al (2002). Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: A phase I study of ZYC101. Clin Cancer Res 8, 1028-37
42. Kanai F, Kawakami T, Hamada H, et al (1998). Adenovirusmediated transduction of Escherichia coli uracil phosphoribosyltransferase gene sensitizes cancer cells to low concentrations of 5-fluorouracil. Cancer Res 58, 1946-51.
43. Kunz M TA, Goebeler M, Engelhardt E, Bröcker E, Gillitzer R (1999). Strong expression of the lymphoattractant C-X-C chemokine Mig is associated with heavy infiltration of T cells in human malignant melanoma. J Pathol 189, 552-8.
44. Kopp HG, Ramos CA, Rafii S (2006). Contribution of endothelial progenitors and proangiogenic hematopoietic cells to vascularization of tumor and ischemic tissue. Curr Opin Hematol 13, 175-81.
45. Kumar V, Sercarz E (1996). Genetic vaccination: The advantages of going naked. Nat Med 2, 857-9.
46. Logan AC, Lutzko C, Kohn DB (2002). Advances in lentiviral vector design for gene-modification of hematopoietic stem cells. Curr Opin Biotechnol 13, 429-36.
47. Lotze MT (1997). Getting to the source: Dendritic cells as therapeutic reagents for the treatment of patients with cancer. Ann Surg 226, 1-5
48. Lowenberg B, Griffin JD, Tallman MS (2003). Acute myeloid leukemia and acute promyelocytic leukemia. Hematology Am Soc Hematol Educ Program 82-101.
49. Luis SF, Eckhard RP (2005). Lung Cancer Immunotherapy. Clin Med Res 3, 221-28.
50. Mahoney BP, Baggett B, Gillies RJ (2003). Tumor acidity, ion trapping and chemotherapeutics. I. Acid pH affects the distribution of chemotherapeutic agents in vitro. Biochem Pharmacol 66, 1207-18.
51. Morgan RA, Dudley ME, Wunderlich JR (2006). Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 314(5796), 126-9
52. Marina Mata JCG, David J. Fink (2003). Gene Transfer to the Nervous System: Prospects for Novel Treatments Directed at Diseases of the Aging Nervous System. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 58, M1111-18
53. Mimeault M, Batra SK (2006). Concise review: recent advances on the significance of stem cells in tissue regeneration and cancer therapies. Stem Cells 24, 2319-45.
54. Mimeault M, Batra SK (2007). Interplay of distinct growth factors during epithelial mesenchymal transition of cancer progenitor cells and molecular targeting as novel cancer therapies. Ann Oncol 18, 1605-19.
55. Mathe G, Halle-Pannenko O, Bourut C (1973). BCG in cancer immunotherapy: Results obtained with various BCG preparations in a screening study for systemic adjuvants applicable to cancer immunoprophylaxis or immunotherapy. Natl Cancer Inst Monogr 39, 107-13.
56. Martin-Orozco N, Dong C (2006). New battle fields for costimulation. J Exp Med 203, 817-20.
57. Mimeault M, Brand RE, Sasson AA, Batra SK(2005). Recent advances on the molecular mechanisms involved in pancreatic cancer progression and therapies. Pancreas 31, 301-16.
58. Mimeault M, Batra SK (2006). Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies. Carcinogenesis 27, 1-22.
59. Marshall JL, Hoyer RJ, Toomey MA, et al (2000). Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anticarcinoembryonic antigen immune responses. J Clin Oncol 18, 3964-73
60. Mincheff M, Tchakarov S, Zoubak S, et al (2000). Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: A phase I/II clinical trial. Eur Urol 38, 208-17.
61. Mabjeesh N J, Simons J W (2002). Gene therapy of prostate cancer: current and future directions. Endocrine-Related Cancer 9, 115-39.
62. Nuyts S VML, Theys J, Landuyt W, Lambin P, Anné J (2002). Clostridium spores for tumor-specific drug delivery. Anticancer Drugs 13, 115-25.
63. Niethammer AG, Xiang R, Becker JC, et al (2002). A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med 8, 1369-75.
64. Ohtani H (1998). Stromal reaction in cancer tissue: pathophysiologic significance of the expression of matrixdegrading enzymes in relation to matrix turnover and immune/inflammatory reactions. Pathol Int 48,1-9.
65. Pouysségur J DF, Mazure NM (2006). Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 441, 437-43.
66. Petrulio CA, Kim-Schulze S, Kaufman HL (2006). The tumour microenvironment and implications for cancer immunotherapy. Expert Opin Biol Ther 6, 671-84.
67. Pule BC, Heslop HE (2002). Genetically engineered T-cells for adoptive immunotherapy. Curr Opin Mol Ther ; 4, 467-75.
68. Philip W, Wong CL, Ian F (2005). Tannock Reduction of Intracellular pH as a Strategy to Enhance the pH-Dependent Cytotoxic Effects of Melphalan for Human Breast Cancer Cells Clinical Cancer Research 11, 3553-7.
69. Palucka AK, Joseph W F, Jacques B (2007). Taming cancer by inducing immunity via dendritic cells. Immunological Reviews 220, 129-50.
70. Roth MD, Gitlitz BJ, Kiertscher SM, et al (2000). Granulocyte macrophage colony-stimulating factor and interleukin 4 enhance the number and antigen-presenting activity of circulating CD14+ and CD83+ cells in cancer patients. Cancer Res 60, 1934-41.
71. Rafiq K, Bergtold A, Clynes R (2002). Immune complex-mediated antigen presentation induces tumor immunity. J Clin Invest 110, 71-79.
72. Reilly RT, Gottlieb MB, Ercolini AM, et al (2000). HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice. Cancer Res 60, 3569-76.
73. Rosenberg SA, Zhai Y, Yang JC, et al (1998). Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J Natl Cancer Inst 90, 1894-1900.
74. Ramshaw IA, Ramsay AJ (2000). The prime-boost strategy: Exciting prospects for improved vaccination. Immunol Today 21, 163-5.
75. Rosenberg SA, Spiess P, Lafreniere R (1986). A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233, 1318-1321.
76. Rosenberg SA, Lotze MT, Muul LM, et al (1987). A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316, 889-97.
77. Ribas A, Butterfield LH, Economou JS (2000). Genetic immunotherapy for cancer. Oncologist 5, 87-98.
78. Shicang Y, Guijun H, Guisheng Q, Yuying L, Guoming W, Ruiling G (2007). Efficacy of chemotherapeutic agents under hypoxic conditions in pulmonary adenocarcinoma multidrug resistant cell line. J Chemother 19, 203-11.
79. Suciu-Foca N, Manavalan JS, Cortesini R (2003). Generation and function of antigen-specific suppressor and regulatory T cells. Transpl Immunol 11, 235-44.
80. Sallusto FA (1994). Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 179, 1109-18.
81. Steinman RM, Turley S, Pierre P, Mellman I (1999). Antigen capture, processing, and presentation by dendritic cells: recent cell biological studies. Hum Immunol 60,562-7.
82. Seo N, Hayakawa S, Takigawa M, Tokura Y (2001). Interleukin-10 expressed at early tumour sites induces subsequent generation of CD4(+) T-regulatory cells and systemic collapse of antitumour immunity. Immunology 103, 449-57.
83. Sioud M FG, Cekaite L (2007). Suppression of immunostimulatory siRNA-driven innate immune activation by 2'-modified RNAs. Biochem Biophys Res Commun 361, 122-6.
84. Shakhar Guy B-ES (2003). Potential Prophylactic Measures Against Postoperative Immunosuppression: Could They Reduce Recurrence Rates in Oncological Patients? . Annals of Surgical Oncology 10, 972-92.
85. Sondak VK, Liu PY, Tuthill RJ, et al (2002). Adjuvant immunotherapy of resected, intermediate-thickness, nodenegative melanoma with an allogeneic tumour vaccine: Overall results of a randomized trial of the Southwest Oncology Group. J Clin Oncol 20, 2058-66
86. Sobol RE, Fakhrai H, Shawler D, et al (1995). Interleukin-2 gene therapy in a patient with glioblastoma. Gene Ther 2, 164-7.
87. Shibata T GAJ, Brown J M (2000). Development of a hypoxiaresponsive vector for tumor-specific gene therapy. Gene therapy 7, 493-8.
88. Tatum JL, Kelloff GJ, Gillies RJ, et al (2006). Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol 82, 699-757.
89. Tlsty TD, Hein PW (2001). Know thy neighbor: stromal cells can contribute oncogenic signals. Curr Opin Genet Dev 11, 54-9.
90. Trédan O GC, Patel K, Tannock IF (2007). Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 99, 1441-54.
91. Tamada K, Tamura H, Flies D, et al (2002). Blockade of LIGHT/LTbeta and CD40 signaling induces allospecific T cell anergy, preventing graft-versus-host disease. J Clin Invest 109,549-57.
92. Van Pel A, Boon T (1982). Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis. Proc Natl Acad Sci USA 79, 4718-22
93. von Euler H, Sadeghi A, Carlsson B, et al (2008). Efficient adenovector CD40 ligand immunotherapy of canine malignant melanoma. J Immunother 31, 377-84.
94. Wu W, Luo Y, Sun C, et al (2006). Targeting cell-impermeable prodrug activation to tumor microenvironment eradicates multiple drug-resistant neoplasms. Cancer Res 66:970-80.
95. Welters MJ, Kenter GG, Piersma SJ, et al (2008). Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin Cancer Res 14, 178-87.
96. Wagner E (2007). Converging Paths of Viral and Non-viral Vector Engineering. Molecular Therapy 16, 1-2.
97. Wolff JA, Malone RW, Williams P, et al (1990). Direct gene transfer into mouse muscle in vivo. Science 247, 1465-8,.
98. Wolfers J, Lozier A, Raposo G, et al (2001). Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat Med 7, 297-303.
99. Yang W, Chen PW, Li H, Alizadeh H, Niederkorn JY (2008). PDL1: PD-1 Interaction Contributes to the Functional Suppression of T-Cell Responses to Human Uveal Melanoma Cells In Vitro. Invest Ophthalmol Vis Sci 49, 2518-25.
100. Zitvogel L, Regnault A, Lozier A, et al (1998). Eradication of established murine tumors using a novel cell-free vaccine: Dendritic cell-derived exosomes. Nat Med 4, 594-600.